Drug interactions
Lorlatinib + Sofosbuvir-velpatasvir
Severity: Moderate
Lorlatinib and Sofosbuvir-velpatasvir: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lorlatinib induces CYP3A4 and may reduce velpatasvir exposure, risking reduced antiviral efficacy. The effect is predicted from the mechanism rather than well characterized clinically.
What this interaction means in plain words
Lorlatinib and Sofosbuvir-velpatasvir can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Lorlatinib belongs to Oncology; Sofosbuvir-velpatasvir belongs to Anti Virals.
Why it happens
Lorlatinib induces CYP3A4 (moderate inducer), increasing velpatasvir metabolism.
What to do
Where possible, delay HCV therapy or choose an alternative to the inducer. If both are needed, monitor HCV RNA and seek specialist advice.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lorlatinib and Sofosbuvir-velpatasvir, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Sofosbuvir-velpatasvir
- Rifampin + Sofosbuvir-velpatasvir Contraindicated
- Rifapentine + Sofosbuvir-velpatasvir Contraindicated
- Sofosbuvir-velpatasvir + St john's wort Contraindicated
- Amiodarone + Sofosbuvir-velpatasvir Major
- Apalutamide + Sofosbuvir-velpatasvir Major
- Carbamazepine + Sofosbuvir-velpatasvir Major
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Frequently asked questions
Can I take Lorlatinib with Sofosbuvir-velpatasvir?
MediHelp rates the interaction as moderate. Lorlatinib and Sofosbuvir-velpatasvir can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lorlatinib induces CYP3A4 and may reduce velpatasvir exposure, risking reduced antiviral efficacy. The effect is predicted from the mechanism rather than well characterized clinically.
How serious is the interaction between Lorlatinib and Sofosbuvir-velpatasvir?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Where possible, delay HCV therapy or choose an alternative to the inducer. If both are needed, monitor HCV RNA and seek specialist advice.
What other medicines interact with Sofosbuvir-velpatasvir?
MediHelp also lists interactions of Sofosbuvir-velpatasvir with, for example, Rifampin, Rifapentine, St john's wort. The full list is on the Sofosbuvir-velpatasvir page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
